Announcements Trials
Browse Landscape

Phase

Phase 3 7Phase 2 3Phase 1/2 2Phase NA 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Large B-Cell, Diffuse 5Prostatic Neoplasms 3Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Lymphoma 2Triple Negative Breast Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Immunoblastic Lymphadenopathy 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Adenocarcinoma 1

Interventions

Rituximab 56Cyclophosphamide 39fludarabine 23fludarabine phosphate 18Peripheral Blood Stem Cell Transplantation 17Lenalidomide 14Melphalan 13Etoposide 12venetoclax 11Whole-Body Irradiation 11Mycophenolic Acid 11obinutuzumab 10Vincristine 10Prednisone 10Bendamustine Hydrochloride 10Doxorubicin 9Cytarabine 9Cyclosporine 9Bortezomib 9Filgrastim 8pembrolizumab 7Nivolumab 7Gemcitabine 7Busulfan 7acalabrutinib 6Tacrolimus 6Interleukin-2 6Dexamethasone 6Carmustine 6Alemtuzumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, Non-Hodgkin × Prednisolone × Clear all
NCT03571308 2023-09-28

ACCEPT

University Hospital Southampton NHS Foundation Trust

Phase 1/2 Completed
39 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

NCT01992653 2023-03-14

A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma

Genentech, Inc.

Phase 1/2 Completed
85 enrolled 34 charts
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡